Hepatic coma in cirrhosis, portal hypertension, and following portacaval shunt. Its etiologies and the current status of its treatment.
D000208:Acute Disease; D000596:Amino Acids / Q000633:toxicity; D000641:Ammonia / Q000009:adverse effects; D001921:Brain / Q000378:metabolism; D002908:Chronic Disease; D003106:Colon / Q000601:surgery; D004044:Dietary Proteins / Q000378:metabolism; D005227:Fatty Acids / Q000009:adverse effects; D005973:Glutamine / Q000009:adverse effects; D006501:Hepatic Encephalopathy / Q000139:chemically induced / Q000150:complications / Q000188:drug therapy / Q000209:etiology* / Q000628:therapy; D006801:Humans; D006975:Hypertension, Portal / Q000150:complications*; D007792:Lactulose / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000150:complications*; D009355:Neomycin / Q000627:therapeutic use; D018377:Neurotransmitter Agents / Q000009:adverse effects; D011167:Portacaval Shunt, Surgical / Q000009:adverse effects*; D011183:Postoperative Complications; D013242:Sterilization; D014510:Urease / Q000037:antagonists & inhibitors
D000596:Amino Acids; D004044:Dietary Proteins; D005227:Fatty Acids; D018377:Neurotransmitter Agents; D005973:Glutamine; D007792:Lactulose; D000641:Ammonia; D014510:Urease; D009355:Neomycin